If I had any kind of HER2+ cancer at any stage I would be trying to see if Perjeta might be a possibility as it increases the likelihood of a pathological complete response which in turn improves survival chances. However it might not be indicated in some circumstances and might not be possible to get it without paying for it. It might be overkill for some smaller cancers without lymph involvement if Herceptin alone could have similar results. I know that I was lucky to get it and I would like anyone who could benefit from it to also get it.
I am still hoping for the pathological complete response, however given the findings of the Katherine trial it seems that it is not the end of the world if there is residual cancer, as Kadcyla (if it can be got) greatly improves survival and decreases recurrence outcomes. Hopefully that should mean that it will be added on the PBS for HER2+ EBC where neoadjuvant treatment has not fully knocked over the cancer.
Katherine Trial:
https://www.nejm.org/doi/full/10.1056/NEJMoa1814017
"Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T-DM1 than with trastuzumab alone."
I read far too many oncology journal articles these days! Thanks for wishing me luck. we all need a bit!